Clinical Trial

A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This single-arm, open-label multicenter Phase I/II study will evaluate the safety, tolerability, anti-tumor activity, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of C-CAR031 in adult participants with GPC3+ advanced/recurrent HCC, who have progressed or are intolerant to at least two prior lines of standardized systemic therapy, and lack of other effective treatments.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-09-05; most recent amendment 2025-12-28.
Status change: Not Yet Recruiting → Recruiting 2025-12-28
Trial Details
NCT Number NCT06590246
Lead Sponsor Shanghai AbelZeta Ltd.
Conditions Hepatocellular Carcinoma
Enrollment 121 participants
Start Date 2024-09-30
Primary Completion 2030-04-30 (estimated)
Study Completion 2043-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-02